Article

Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals

CHOC Children's, Orange, California, USA.
Genetics in medicine: official journal of the American College of Medical Genetics (Impact Factor: 7.33). 05/2011; 13(5):457-84. DOI: 10.1097/GIM.0b013e318211a7e1
Source: PubMed

ABSTRACT

To develop educational guidelines for the diagnostic confirmation and management of individuals identified by newborn screening, family-based testing after proband identification, or carrier testing in at-risk populations, and subsequent prenatal or postnatal testing of those who are presymptomatic for a lysosomal storage disease.
Review of English language literature and discussions in a consensus development panel comprised an international group of experts in the clinical and laboratory diagnosis, treatment and management, newborn screening, and genetic aspects of lysosomal storage diseases.
Although clinical trial and longitudinal data were used when available, the evidence in the literature is limited and consequently the recommendations must be considered as expert opinion. Guidelines were developed for Fabry, Gaucher, and Niemann-Pick A/B diseases, glycogen storage type II (Pompe disease), globoid cell leukodystrophy (Krabbe disease), metachromatic leukodystrophy, and mucopolysaccharidoses types I, II, and VI.
These guidelines serve as an educational resource for confirmatory testing and subsequent clinical management of presymptomatic individuals suspected to have a lysosomal storage disease; they also help to define a research agenda for longitudinal studies such as the American College of Medical Genetics/National Institutes of Health Newborn Screening Translational Research Network.

Download full-text

Full-text

Available from: Raymond Y Wang, Mar 11, 2014
  • Source
    • "Because of the complex symptomatology, the accurate diagnosis of all LSDs, not just of Schindler disease, merely by clinical examination , is highly improbable. [12] For the diagnosis of this group of genetic disorders, complex biochemical and molecular genetic tests are required. The tests are carried out in two directions: based on enzyme-level activity quantification in urine, blood, amniotic fluid, skin fibroblasts and tissue biopsies; [13] [14] [15] [16] [17] [18] and on the most common screening tests, which emphasize the presence of certain glycosphingolipids, glycosaminoglycans and oligosaccharides in urine and/or blood. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schindler disease is an inherited metabolic disorder caused by the deficient activity of α-N-acetylgalactosaminidase enzyme. An accurate diagnosis requires, besides clinical examination, complex and costly biochemical and molecular genetic tests. In the last years, mass spectrometry (MS) based on nanofluidics and high-resolution instruments has become a successful alternative for disease diagnosis based on the investigation of O-glycopeptides in patient urine. A complex mixture of glycoforms extracted from the urine of a 3-year-old patient was investigated by Orbitrap MS equipped with Nanospray Flex Ion Source in the negative ion mode. For structural characterization of several molecular species, collision-induced dissociation MS2–MS3 was carried out using collision energy values within 20–60 eV range. By our approach, 39 novel species associated to this condition were identified, among which O-glycopeptides, free O-glycans and one structure corresponding to an N-glycan never characterized in the context of Schindler disease. The experiments conducted at a resolution of 60 000 allowed the discrimination and identification of a total number of 69 different species with an average mass accuracy of 9.87 ppm, an in-run reproducibility of almost 100%, an experiment-to-experiment and day-to-day reproducibility of about 95%. This study brings contributions in the diagnosis of Schindler disease through the elucidation of potential biomarker species in urine. Our multistage MS results completed with 39 new glycoforms the inventory of potential biomarker structures associated to Schindler disease. For the first time, an N-glycan was identified and structurally characterized in Schindler patient urine, which opens new research directions in the field. Copyright
    Full-text · Article · Sep 2015 · Journal of Mass Spectrometry
  • Source
    • "Specific GALC missense alleles (p.G57S, p.W115R and p.G286D) are associated with late-onset Krabbe disease (Lissens et al., 2007). Many infants with very low GALC activity on newborn screening have remained asymptomatic over several years (Wang et al., 2011) and at what age, if ever, these individuals will develop symptomatic Krabbe disease is unclear. Lateonset Krabbe disease typically presents in adolescence or adulthood with insidiously progressive paraparesis and gait disturbance which can appear similar to progressive multiple sclerosis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Several single gene disorders share clinical and radiologic characteristics with multiple sclerosis and have the potential to be overlooked in the differential diagnostic evaluation of both adult and paediatric patients with multiple sclerosis. This group includes lysosomal storage disorders, various mitochondrial diseases, other neurometabolic disorders, and several other miscellaneous disorders. Recognition of a single-gene disorder as causal for a patient's 'multiple sclerosis-like' phenotype is critically important for accurate direction of patient management, and evokes broader genetic counselling implications for affected families. Here we review single gene disorders that have the potential to mimic multiple sclerosis, provide an overview of clinical and investigational characteristics of each disorder, and present guidelines for when clinicians should suspect an underlying heritable disorder that requires diagnostic confirmation in a patient with a definite or probable diagnosis of multiple sclerosis. © The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
    Full-text · Article · Jan 2015 · Brain
  • Source
    • "MPS-VI (Maroteaux-Lamy syndrome) is an autosomal recessive condition due to arylsulfatase B deficiency . Although therapies are available for many MPS disorders, notably enzyme replacement therapy (ERT) and hematopoietic cell transplantation (HCT) [12] [13] [14] [15] [16] [17] [18] [19] [20], their beneficial effect on the skeleton is thought to be limited if not initiated early [21]. As new therapies become available, development of biomarkers that are associated with the skeletal manifestations in MPS disorders would be helpful for clinical trials. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Skeletal disease causes significant morbidity in mucopolysaccharidoses (MPS), and bone remodeling processes in MPS have not been well characterized. The objective of this study was to determine if biomarkers of bone turnover are abnormal in children with specific MPS disorders (i.e. MSP-I, MPS-II, and MPS-VI) compared to healthy children. Methods: A cross-sectional study was performed of serum biomarkers of bone formation (bone-specific alkaline phosphatase [BSAP], osteocalcin) and urine biomarkers of bone resorption (pyridinoline, deoxypyridinoline) in MPS and healthy controls. Measures of physical function and pain were obtained using the Children's Health Questionnaire (CHQ). Results: The cohort consisted of 39 children with MPS (MPS-I=26; MPS-II=11; MPS-VI=4) and 51 healthy children. Adjusting for sex and Tanner stage group, MPS individuals had statistically significant increases for osteocalcin (p< 0.001), with trends toward higher BSAP (p=0.054) and urinary pyridinoline (p=0.084). These biomarkers were not significantly associated with CHQ bodily pain and physical-function scores. Conclusion: Osteocalcin was increased in children with MPS disorders, with trends for increases in BSAP and urinary pyridinoline, suggesting that bone remodeling is altered in children with MPS. Future studies to assess the ability of these biomarkers to quantify and monitor MPS skeletal disease in response to therapy are needed.
    Full-text · Article · Aug 2014 · Journal of pediatric rehabilitation medicine
Show more